Loading data for NGNE — first visit, this takes a few seconds.
Neurogene Inc.
35.48 -0.64 (-1.77%)
- Capitalización de mercado
- $704.6M
- Volumen
- 181K
- Próxima fecha de resultados
- Nov 12, 2026
Neurogene Inc. (NGNE): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$1,53 | -$0,16 | -41.67% |
Métricas
- Precio de compra
- 25.99
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -111M
- 1.96
- -5.04
- n/a
- -6.8
- P/B (TTM)
- 2.57
- P/S (TTM)
- n/a
- Fecha de resultados
- Nov 12, 2026
- Precio de venta
- 44.63
- Volumen
- 181,388
- Volumen medio (20D)
- 238,896
- Abierto
- 36.50
- Anterior Cerrar
- 36.12
- Rango del día
- 35.38 - 37.64
- Rango de 52 semanas
- 15.93 - 43.66
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Neurogene Inc.
Ver perfil →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Industria Biotechnology
Sector Healthcare
IPO Fecha Mar 7, 2014
Empleados 131
Bolsa de Valores NasdaqGM
Símbolo bursátil NGNE
Sitio web https://www.neurogene.com